On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading
On January 10, 2023, twenty-five Members of Congress sent a letter to HHS Secretary Xavier Becerra urging him to act on the Xtandi request, and to use the Bayh-Dole Act to lower the price of Xtandi (enzalutamide) for US patients.… Continue Reading
While much attention has been focused on negotiations at the World Health Organization (WHO) on a pandemic treaty, there has been less scrutiny on WHO deliberations on proposed amendments to the International Health Regulations (2005). The reasons are two-fold: 1)… Continue Reading
On 7 December 2022, Knowledge Ecology International (KEI) delivered the following statement on the proposed Enlarged Conference of the Parties (E-COP) of the conceptual zero draft at the third session of the WHO Intergovernmental Negotiating Body to draft and negotiate… Continue Reading
On 6 December 2022, Knowledge Ecology International (KEI) delivered the following statement on Article 9 – Fair, equitable and timely access and benefit-sharing of the conceptual zero draft at the third session of the WHO Intergovernmental Negotiating Body to draft… Continue Reading
On 6 December 2022, Knowledge Ecology International (KEI) delivered the following statement on Chapter III (Achieving equity in, for and through pandemic prevention, preparedness, response and recovery of health system) of the conceptual zero draft at the third session of… Continue Reading
On 16 November 2022, the Bureau of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (INB) released the conceptual zero draft in all six official languages… Continue Reading
NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to… Continue Reading
Attached is a letter from 19 groups asking HHS Secretary Xavier Becerra to take action on the request that HHS use the federal government rights in patents on the prostate drug enzalutamide, marketed by Astellas under the brand name Xtandi.… Continue Reading
This is what delegates will be discussing at the next INB meeting the week of December 5, 2022, in Geneva. ADVANCE_for_16_November_A_INB3_3_E From the document: “In preparing a conceptual zero draft, the Bureau started by integrating the above-mentioned input into the… Continue Reading